Nimodipine-d7

Nimodipine-d7 is the deuterium labeled Nimodipine. Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1].

Product Specifications

CAS Number

[1246815-36-0]

Product Name Alternative

BAY-e 9736-d7

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Calcium Channel; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Autophagy; Membrane Transporter/Ion Channel; Neuronal Signaling; Others

Field of Research

Cardiovascular Disease; Cancer

Purity

99.35

Solubility

DMSO : 100 mg/mL (ultrasonic; warming)

Smiles

O=C(C1=C(C)NC(C)=C(C(OC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCOC

Molecular Formula

C21H19D7N2O7

Molecular Weight

425.48

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Langley, M.S., et al. Nimodipine. Drugs 37, 669–699 (1989) .|[3] Marbacher S, et al. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34 (5) :932-938.|[4]Honn KV, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984;2 (1) :61-72.